RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting...

RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world’s first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen’s clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fibrotic efficacy NANTONG, China, July 31, 2026 /PRNewswire/ — Ractigen Therapeutics, a pioneer […]

Ractigen Therapeutics announces groundbreaking FDA IND clearance for RAG-1C, a first-of-its-kind saRNA therapy targeting Proliferative Vitreoretinopathy, offering new hope in ocular treatment.